Metabolic syndrome-breast cancer link varies by intrinsic molecular subtype
Immacolata Capasso(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Giuseppe D’Aiuto(Memorial Sloan Kettering Cancer Center), Gerardo Botti(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Michelino De Laurentiis(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Antonella Petrillo(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Ernesta Cavalcanti(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Massimiliano D’Aiuto(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Maria Grimaldi(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Anna Crispo(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Carmela Coppola, Gennaro Ciliberto(Istituti Fisioterapici Ospitalieri), Nicola Maurea(Cancer Institute (WIA)), Alfredo Fucito(Serviço Nacional de Aprendizagem Comercial), Emanuela Esposito(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Maurizio Montella(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), G. Frasci(Radiation Oncology Institute)
Cited by 22
Related Papers
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial
|The Lancet Oncology|2018|1k
Cancer classification using the Immunoscore: a worldwide task force
|Journal of Translational Medicine|2012|803
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|743
<i>BRAF/NRAS</i> Mutation Frequencies Among Primary Tumors and Metastases in Patients With Melanoma
|Journal of Clinical Oncology|2012|460
Gemcitabine Plus Vinorelbine Versus Vinorelbine Alone in Elderly Patients With Advanced Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2000|452